<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="6067">13-cis retinoic acid</z:chebi> + (OH)2 vitamin D3 + low-dose 6-thioguanine and <z:chebi fb="0" ids="28680">cytarabine</z:chebi> were tested in 26 patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and in 4 patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) (median age 72.5), ineligible for standard chemotherapy </plain></SENT>
<SENT sid="1" pm="."><plain>The response rate was 50%, with 27% complete remission </plain></SENT>
<SENT sid="2" pm="."><plain>The median survival of the whole group and responders was 7.5 (1-47+) and 16.5 months (3.5-47+), respectively </plain></SENT>
</text></document>